Abstract
The initial phase of the COVID-19 pandemic in the US was marked by limited diagnostic testing, resulting in the need for seroprevalence studies to estimate cumulative incidence and define epidemic dynamics. In lieu of systematic representational surveillance, venue-based sampling was often used to rapidly estimate a community’s seroprevalence. However, biases and uncertainty due to site selection and use of convenience samples are poorly understood. Using data from a SARS-CoV-2 serosurveillance study we performed in Somerville, Massachusetts, we found that the uncertainty in seroprevalence estimates depends on how well sampling intensity matches the known or expected geographic distribution of seropositive individuals in the study area. We use GPS-estimated foot traffic to measure and account for these sources of bias. Our results demonstrated that study-site selection informed by mobility patterns can markedly improve seroprevalence estimates. Such data should be used in the design and interpretation of venue-based serosurveillance studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Andrew and Corey Morris-Singer Foundation, National Cancer Institute at the National Institutes of Health [U01CA261277] and the National Institute of Allergy and Infectious Diseases at the National Institutes of Health [T32AI007061 to TSB]. This project has been funded in part by contract 200-2016-91779 with the Centers for Disease Control and Prevention. The findings, conclusions, and views expressed in this presentation are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was designated minimal risk human subjects research and approved by institutional review boards at Massachusetts General Hospital and the Harvard T.H. Chan School of Public Health (Protocol number:2020P001081).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵** Joint senior authors
Data Availability
The data used in this study are available either via publicly available sources (for business foot traffic data) or via request of the study authors (serological data).
